Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2-Reference-Cited by-同舟云学术

Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2

Published:2023 Issue:13 Volume:13 Page:8779-8793
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Tsuji Kohei¹^ORCID,Baffour-Awuah Owusu Kofi¹,Miura Yutaro¹,Ishii Takahiro¹,Shinohara Kouki¹,Kobayakawa Takuya¹^ORCID,Emi Akino²,Nakano Takashi²,Suzuki Youichi²,Tamamura Hirokazu¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), Chiyoda-ku, Tokyo 101-0062, Japan

2. Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan

Abstract

C-Terminally dimerized HR2 peptides of SARS-CoV-2 showed significantly higher antiviral activity than the corresponding monomers. Our dimerization strategy of HIV-1 fusion inhibitors successfully facilitated the design of potent inhibitors of SARS-CoV-2.

Funder

Japan Society for the Promotion of Science

Japan Agency for Medical Research and Development

Astellas Foundation for Research on Metabolic Disorders

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/RA/D2RA07356K

Reference39 articles.

1. World Health Organization , COVID-19 vaccine tracker and landscape , https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines , accessed on 2022-7-6

2. The journey of remdesivir: from Ebola to COVID-19

3. U.S. Food & Drug Administration , FDA approves first treatment for COVID-19 , https://www.fda.gov/news-events/pressannouncements/fda-approves-first-treatment-covid-19 , accessed on 2021-1-21

4. Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50% Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study , Press Release from Merck & Co., Inc. , 2021 , accessed on 2022-5-12

5. World Health Organization , WHO updates its treatment guidelines to include molnupiravir , March 3, 2022 , https://www.who.int/news/item/03-03-2022-molnupiravir , accessed on 2022-5-12

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empowering SARS‐CoV‐2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides;Journal of Medical Virology;2024-03

2. Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion;RSC Chemical Biology;2024

3. Structure and Function of the SARS-CoV-2 6-HB Fusion Core and Peptide-Based Fusion Inhibitors: A Review;Current Medicinal Chemistry;2023-11-24